{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:10:53Z","timestamp":1777486253452,"version":"3.51.4"},"reference-count":53,"publisher":"Akademiai Kiado Zrt.","issue":"30","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,7,30]]},"abstract":"<jats:p>A r\u00e9gen j\u00f3indulat\u00fa tumork\u00e9nt sz\u00e1montartott hypophysisdaganatok ritk\u00e1n agressz\u00edven\n                    viselkednek, \u00e9s metaszt\u00e1zist is adhatnak. Az Eur\u00f3pai Endokrinol\u00f3giai T\u00e1rsas\u00e1g\n                    aktu\u00e1lis ir\u00e1nyelve szerint a hypophysisadenom\u00e1t agressz\u00edvnek tartjuk, ha a\n                    daganat radiol\u00f3giailag invaz\u00edv, \u00e9s szokatlanul gyorsan n\u00f6vekszik, vagy ki\u00fajul az\n                    optim\u00e1lis standard kezel\u00e9s ellen\u00e9re. Jelenleg nem rendelkez\u00fcnk olyan patol\u00f3giai\n                    markerrel, amely egy\u00e9rtelm\u0171en jelezn\u00e9 a daganat agressz\u00edv, illetve malignus\n                    term\u00e9szet\u00e9t. A hypophysiscarcinom\u00e1t ez\u00e9rt jelenleg klinikai ism\u00e9rvek alapj\u00e1n\n                    defini\u00e1ljuk; a carcinoma diagn\u00f3zis\u00e1nak kimond\u00e1s\u00e1hoz craniospinalis \u00e9s\/vagy\n                    t\u00e1voli \u00e1tt\u00e9t igazol\u00e1sa sz\u00fcks\u00e9ges. Az \u00e1tt\u00e9tek jellemz\u0151en \u00e9vekkel a betegs\u00e9g els\u0151\n                    azonos\u00edt\u00e1s\u00e1t k\u00f6vet\u0151en jelennek meg. A sz\u00f6vettani vizsg\u00e1lat utalhat a daganat\n                    agressz\u00edv volt\u00e1ra, ha a Ki67-index \u00e9s a mitotikus r\u00e1ta emelkedett, vagy a p53\n                    immunhisztok\u00e9miailag pozit\u00edv. A betegek r\u00f6vid \u00e9s hossz\u00fa t\u00e1v\u00fa kezel\u00e9s\u00e9t egy\u00e9nre\n                    szabottan, multidiszciplin\u00e1ris hypophysisbizotts\u00e1gban kell meghat\u00e1rozni. A\n                    hypophysisadenom\u00e1k kezel\u00e9s\u00e9ben haszn\u00e1latos standard gy\u00f3gyszereket a m\u00e9g\n                    toler\u00e1lhat\u00f3 maxim\u00e1lis d\u00f3zisban kell alkalmazni. A legt\u00f6bb beteg eset\u00e9ben\n                    ism\u00e9telt m\u0171t\u00e9t(ek)re \u00e9s sug\u00e1rkezel\u00e9sre is sor ker\u00fcl. Ha a daganat m\u00e9gis\n                    progredi\u00e1l, kemoter\u00e1pia ind\u00edt\u00e1sa javasolt, els\u0151k\u00e9nt a temozolomid v\u00e1lasztand\u00f3.\n                    Ezt k\u00f6vet\u0151en az immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3 k\u00e9sz\u00edtm\u00e9nyek, bevacizumab \u00e9s\n                    peptidreceptor-radioter\u00e1pia k\u00f6z\u00fcl v\u00e1laszthatunk. Orv Hetil. 2023; 164(30):\n                    1167\u20131175.<\/jats:p>","DOI":"10.1556\/650.2023.32832","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T07:23:25Z","timestamp":1690701805000},"page":"1167-1175","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":6,"title":["Agressz\u00edv hypophysisadenoma \u00e9s hypophysiscarcinoma"],"prefix":"10.1556","volume":"164","author":[{"given":"Mikl\u00f3s","family":"T\u00f3th","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika, Endo-ERN K\u00f6zpont Budapest, Kor\u00e1nyi S. u. 2\/A, 1083 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly AF","year":"2020","unstructured":"1 Daly AF, Beckers A. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. 2020; 49: 347-355.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"2 Gruppetta","year":"2013","unstructured":"2 Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 2013; 16: 545-553.","journal-title":"Pituitary"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"3 Melmed","year":"2022","unstructured":"3 Melmed S, Kaiser UB, Lopes MB, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022; 43: 1003-1037.","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"4 Raappana","year":"2010","unstructured":"4 Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010; 95: 4268-4275.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011","volume":"171","author":"5 Tj\u00f6rnstrand","year":"2014","unstructured":"5 Tj\u00f6rnstrand A, Gunnarsson K, Evert M, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol. 2014; 171: 519-526.","journal-title":"Eur J Endocrinol"},{"key":"ref5","unstructured":"6 Czirj\u00e1k S, P\u00e1sztor E, Piffk\u00f3 P, et al. Pituitary adenoma over age 60 (experience with the transsphenoidal approach). [Hypophysis adenoma a hatvanadik \u00e9let\u00e9v ut\u00e1n. Transsphenoidalis felt\u00e1r\u00e1ssal szerzett tapasztalatok.] Orv Hetil. 1988; 129: 763-767. [Hungarian]"},{"key":"ref6","unstructured":"7 T\u00f3th M, R\u00e1cz K, Nov\u00e1k K, et al. Regression of a pituitary tumor, associated with primary hyperthyroidism, under the effect of 1-thyroxine. [Primer hypothyreosishoz t\u00e1rsul\u00f3 hypophysis-tumor regressi\u00f3ja l-thyroxin hat\u00e1s\u00e1ra.] Orv Hetil. 1989; 130: 1111-1113. [Hungarian]"},{"key":"ref7","unstructured":"8 T\u00f3th M, R\u00e1cz K, Kiss R, et al. Thyroid-stimulating hormone-secreting pituitary adenoma. [Thyreoidea stimul\u00e1l\u00f3 hormont termel\u0151 hypophysis adenoma.] Orv Hetil. 1994; 135: 2709-2712. [Hungarian]"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Mez\u0151si E, Nemes O. Treatment of pituitary adenomas. [A hypophysisadenom\u00e1k kezel\u00e9se.] Orv Hetil. 2009; 150: 1803-1810. [Hungarian]","DOI":"10.1556\/oh.2009.28584"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10 D\u00e9nes J, Korbonits M, Hubina E, et al. Familial isolated pituitary adenoma syndrome. [Familiaris izol\u00e1lt hypophysisadenoma.] Orv Hetil. 2011; 152: 722-730. [Hungarian]","DOI":"10.1556\/OH.2011.29093"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 G\u00f3th M. Drug therapy for acromegaly. [Az acromegalia gy\u00f3gyszeres kezel\u00e9se.] Orv Hetil. 2013; 154: 1527-1534. [Hungarian]","DOI":"10.1556\/OH.2013.29719"},{"key":"ref11","unstructured":"12 Lloyd RV, Kovacs K, Young WF Jr, et al. Tumours of the pituitary. In: Lellis R, Lloyd R, Heitz P, Eng C. (eds.) WHO classification of tumours - Tumours of endocrine organs: IARC Press, Lyon, 2004; pp. 9-47."},{"key":"ref12","unstructured":"13 Osamura RY, Grossman A, Korbonits M, et al. Pituitary adenomas. In: Lloyd RV, Osamura RY, Kl\u00f6ppel G, et al. (eds.) WHO classification of tumours of endocrine organs. 4th ed. IARC Press, Lyon, 2017; pp. 14-18."},{"key":"ref13","unstructured":"14 Board WCoTE. Endocrine and neuroendocrine tumours. In: WHO classification of tumours series. 5th ed. International Agency for Research on Cancer, Lyon, 2022. Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/36 [accessed: 8 April, 2023]."},{"key":"ref14","unstructured":"15 Mete O, Osamura RY, Asa SL. Pituitary gland: introduction. In: Lloyd RV, Osamura RY, Kl\u00f6ppel G, et al. (eds.) WHO classification of tumours of endocrine organs. 5th ed. IARC Press, Lyon, 2022."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"16 Asa","year":"2022","unstructured":"16 Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022; 33: 6-26.","journal-title":"Endocr Pathol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas - diagnosis and emerging treatments","volume":"10","author":"Ieva A","year":"2014","unstructured":"17 Di Ieva A, Rotondo F, Syro LV, et al. Aggressive pituitary adenomas - diagnosis and emerging treatments. Nat Rev Endocrinol. 2014; 10: 423-435.","journal-title":"Nat Rev Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"18 McCormack","year":"2018","unstructured":"18 McCormack A, Dekkers OM, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018; 178: 265-276.","journal-title":"Eur J Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018; 178: G1-G24.","DOI":"10.1530\/EJE-17-0796"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"20 Dekkers","year":"2020","unstructured":"20 Dekkers OM, Karavitaki N, Pereira AM. The epidemiology of aggressive pituitary tumors (and its challenges). Rev Endocr Metab Disord. 2020; 21: 209-212.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","volume":"156","author":"21 Saeger","year":"2007","unstructured":"21 Saeger W, L\u00fcdecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007; 156: 203-216.","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22 Hansen TM, Batra S, Lim M, et al. Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev. 2014; 37: 279-285. discussion 285-286.","DOI":"10.1007\/s10143-014-0525-y"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"23 Raverot","year":"2021","unstructured":"23 Raverot G, Ilie MD, Lasolle H, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021; 17: 671-684.","journal-title":"Nat Rev Endocrinol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"24 Trouillas","year":"2020","unstructured":"24 Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 2020; 12: 514.","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-020-09562-9","article-title":"Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions","volume":"21","author":"25 Trouillas","year":"2020","unstructured":"25 Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions. Rev Endocr Metab Disord. 2020; 21: 243-251.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1210\/jc.2019-00012","article-title":"Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer","volume":"104","author":"26 Schill","year":"2019","unstructured":"26 Schill F, Nilsson M, Olsson DS, et al. Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer. J Clin Endocrinol Metab. 2019; 104: 3379-3388.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"27 Burman","year":"2022","unstructured":"27 Burman P, Trouillas J, Losa M, et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol. 2022; 187: 593-605.","journal-title":"Eur J Endocrinol"},{"key":"ref27","unstructured":"28 Burman P, Casar-Borota O, Perez-Rivas LG, et al. Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab. 2023 feb. 28. dgad098. Erratum: J Clin Endocrinol Metab. 2023 Apr 27. dgad222."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29 Imber BS, Lin AL, Zhang Z, et al. Comparison of radiographic approaches to assess treatment response in pituitary adenomas: is RECIST or RANO good enough? J Endocr Soc. 2019; 3: 1693-1706.","DOI":"10.1210\/js.2019-00130"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"30 Wen","year":"2010","unstructured":"30 Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-1972.","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fendo.2018.00318","article-title":"Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions","volume":"9","author":"31 Syro","year":"2018","unstructured":"31 Syro LV, Rotondo F, Camargo M, et al. Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions. Front Endocrinol (Lausanne) 2018; 9: 318.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/cancers13061395","article-title":"Large scale molecular studies of pituitary neuroendocrine tumors: novel markers, mechanisms and translational perspectives","volume":"13","author":"32 Peculis","year":"2021","unstructured":"32 Peculis R, Niedra H, Rovite V. Large scale molecular studies of pituitary neuroendocrine tumors: novel markers, mechanisms and translational perspectives. Cancers (Basel) 2021; 13: 1395.","journal-title":"Cancers (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1210\/endrev\/bnaa006","article-title":"Novel insights into pituitary tumorigenesis: genetic and epigenetic mechanisms","volume":"41","author":"Srirangam Nadhamuni V","year":"2020","unstructured":"33 Srirangam Nadhamuni V, Korbonits M. Novel insights into pituitary tumorigenesis: genetic and epigenetic mechanisms. Endocr Rev. 2020; 41: 821-846.","journal-title":"Endocr Rev"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/PAS.0b013e31815ade45","article-title":"Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients","volume":"32","author":"34 Trouillas","year":"2008","unstructured":"34 Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008; 32: 534-543.","journal-title":"Am J Surg Pathol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1210\/JC.2015-2015","article-title":"Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG)","volume":"100","author":"Laat JM","year":"2015","unstructured":"35 de Laat JM, Dekkers OM, Pieterman CR, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab. 2015; 100: 3288-3296.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"36 Verg\u00e8s","year":"2002","unstructured":"36 Verg\u00e8s B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002; 87: 457-465.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-014-1285-z","article-title":"Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations","volume":"128","author":"Kock L","year":"2014","unstructured":"37 De Kock L, Sabbaghian N, Plourde F, et al. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 2014; 128: 111-122.","journal-title":"Acta Neuropathol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"38 Casar-Borota","year":"2021","unstructured":"38 Casar-Borota O, Boldt HB, Engstr\u00f6m BE, et al. Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab. 2021; 106: 1183-1194.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.yfrne.2020.100852","article-title":"The tumour microenvironment of pituitary neuroendocrine tumours","volume":"58","author":"39 Marques","year":"2020","unstructured":"39 Marques P, Grossman AB, Korbonits M. The tumour microenvironment of pituitary neuroendocrine tumours. Front Neuroendocrinol. 2020; 58: 100852.","journal-title":"Front Neuroendocrinol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","article-title":"The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications","volume":"25","author":"40 Marques","year":"2022","unstructured":"40 Marques P, Silva AL, L\u00f3pez-Presa D, et al. The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary 2022; 25: 363-382.","journal-title":"Pituitary"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/ERC-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review","volume":"29","author":"41 Ilie","year":"2022","unstructured":"41 Ilie MD, Vasiljevic A, Jouanneau E, et al. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocr Relat Cancer 2022; 29: 415-426.","journal-title":"Endocr Relat Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"42 Ono","year":"2008","unstructured":"42 Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008; 93: 4721-4727.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43 Lasolle H, Ilie MD, Raverot G. Aggressive prolactinomas: how to manage? Pituitary 2020; 23: 70-77.","DOI":"10.1007\/s11102-019-01000-7"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/medicina58081095","article-title":"Treatment of prolactinoma","volume":"58","author":"Inder WJ","year":"2022","unstructured":"44 Inder WJ, Jang C. Treatment of prolactinoma. Medicina (Kaunas) 2022; 58: 1095.","journal-title":"Medicina (Kaunas)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"45 Fleseriu","year":"2021","unstructured":"45 Fleseriu M, Biller BM, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021; 24: 1-13.","journal-title":"Pituitary"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"46 Fleseriu","year":"2021","unstructured":"46 Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021; 9: 847-875.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"47 Pivonello","year":"2022","unstructured":"47 Pivonello R, Zacharieva S, Elenkova A, et al. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 2022; 25: 911-926.","journal-title":"Pituitary"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48 Lam G, Mehta V, Zada G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg Focus. 2012; 32: E2.","DOI":"10.3171\/2012.4.FOCUS1268"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49 Syro LV, Rotondo F, Ortiz LD, et al. 65 years of the double helix. Treatment of pituitary tumors with temozolomide: an update. Endocr Relat Cancer 2018; 25: T159-T169.","DOI":"10.1530\/ERC-18-0015"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"50 Stupp","year":"2005","unstructured":"50 Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51 Lin AL, Sum MW, DeAngelis LM. Is there a role for early chemotherapy in the management of pituitary adenomas? Neuro Oncol. 2016; 18: 1350-1356.","DOI":"10.1093\/neuonc\/now059"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52 Whitelaw BC. How and when to use temozolomide to treat aggressive pituitary tumours. Endocr Relat Cancer. 2019; 26: R545-R552.","DOI":"10.1530\/ERC-19-0083"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/a-1260-3975","article-title":"Experience with 3 patients","volume":"129","author":"53 Osterhage","year":"2021","unstructured":"53 Osterhage K, Rotermund R, Droste M, et al. Bevacizumab in aggressive pituitary adenomas. Experience with 3 patients. Exp Clin Endocrinol Diabetes 2021; 129: 178-185.","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/30\/article-p1167.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/30\/article-p1167.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/30\/article-p1167.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T13:16:02Z","timestamp":1697807762000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/30\/article-p1167.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":53,"journal-issue":{"issue":"30"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32832","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]}}}